Perceptive solutions to anti-filarial chemotherapy of lymphatic filariasis from the plethora of nanomedical sciences

Journal of Drug Targeting

Volumn 22, Issue 1, 2014, Pages 1-13

  Ali, Mohammad ^a   Afzal, Mohammad ^b   Kaushik, Ujjwal ^c   Bhattacharya, Shailja Mishra ^d   Ahmad, Farhan Jalees ^c   Dinda, Amit Kumar ^e  

^a HAMDARD UNIVERSITY   (India)

^b Dabur Research and Development Centre   (India)

^c HAMDARD UNIVERSITY   (India)

^d CENTRAL DRUG RESEARCH INSTITUTE   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti filarial chemotherapy; Anti filarial drugs; Lymphatic filariasis; Nanodrug delivery system; Nanomedicines; Nanotechnology

Indexed keywords

ALBENDAZOLE; ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; LIPOSOMAL DIETHYLCARBAMAZINE PLUS DOXYRUBICIN; LIPOSOMAL DIETHYLCARBAMAZINE PLUS DOXYRUBICIN PLUS RIFAMPICIN; LIPOSOMAL DIETHYLCARBAMAZINE PLUS RIFAMPICIN; RIFAMPICIN; TETRACYCLINE; TOCOFERSOLAN; TUFTSIN; UNCLASSIFIED DRUG;

CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; FEVER; FILARIA; GASTROINTESTINAL ABSORPTION; HUMAN; INFLAMMATION; LIPOSOMAL DELIVERY; LIVER TOXICITY; LYMPHATIC FILARIASIS; MINIMUM INHIBITORY CONCENTRATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VECTOR CONTROL;

ANIMALS; DRUG DELIVERY SYSTEMS; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS;

EID: 84890402074     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.832766     Document Type: Review

References (88)

1. Wagner V, Dullaart AK, Zweck A, et al. The emerging nanomedicine landscape. Nat Biotechnol 2006;24:1211-7.
2. Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine 2009;4:105-18.
3. Lisziewicz J, To00 ke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine 2013;9:28-38.
4. Pourmand A, Pourmand MR, Wang J, et al. Application of nanomedicine in emergency medicine; point-of-care testing and drug delivery in twenty-first century. DARU J. Pharm Sci 2012; 20:20-6.
5. Owais M, Misra-bhattacharya S, Haq W, et al. Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis. J Drug Target 2003;11: 247-51.
6. Bajpai P, Vedi S, Owais M, et al. Use of liposomized tetracycline inelimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model. J Drug Target 2005;13: 375-81.
7. Dangi A, Dwivedi V, Vedi S, et al. Improvement in the antifilarial efficacy of doxycycline and rifampicin by combination therapy and drug delivery approach. J Drug Target 2010;18:343-50.
8. Kirthi AV, Rahuman AA, Rajakuma G, et al. Acaricidal, pediculocidal and larvicidal activity of synthesized ZnO nanoparticles using wetchemical route against blood feeding parasites. Parasitol Res 2011;5:47-56.
9. Ramyadevi J, Jeyasubramanian K, Marikani A, et al. Copper nanoparticles synthesized by polyol process used to control hematophagous parasites. Parasitol Res 2011;5:56-67.
10. Salunkhe RB, Patil SV, Patil CD, et al. Larvacidal potential of silver nanoparticles synthesized using fungus Cochliobolus lunatus against Aedes aegypti and Anopheles stephensi Liston. Parasitol Res 2011;109:823-31.
11. Ali M, Afzal M, Verma M, et al. Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. Parasitol Res 2013;2: 2933-43. doi: 10.1007/s00436-013-3466-4.
12. Edwards G, Krishna S. Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections. Eur J Clin Microbiol Infect Dis 2004;23:233-42.
13. Singh PK, Ajay A, Kushwaha S, et al. Towards novel antifilarial drugs: challenges and recent developments. Future Med Chem 2010;2:251-83.
14. Melrose WD. Chemotherapy for lymphatic filariasis progress but not perfection. Expert Rev Anti Infect Ther 2003;1:571-7.
15. Global programme to eliminate lymphatic filariasis: progress report, 2011. Wkly Epidemiol Rec 2012;87:346-56.
16. Anitha K, Shenoy RK. Treatment of lymphatic filariasis: current trends. Continuing Med Education 2001;67:60-5.
17. Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine-an overview. Fundam Clin Pharmacol 2009;23: 263-9.
18. Teli MK, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des 2010;16:1882-92.
19. Darshan S, Tyshenko MG. Identifying recent trends in nanomedicine development. Int J Nanotechnol 2010;7:173-86.
20. Petrak K. Essential properties of drug-targeting delivery systems. Drug Discov Today 2005;23-24:1667-73.
21. Takakura Y. Development of drug delivery systems for macromolecular drugs. Yakugaku Zasshi 1996;116:519-32 (in Japanese).
22. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008;36:43-8.
23. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44: 235-49.
24. Garc?́a-Rodriguez JJ, Torrado J, Bolás F. Improving bioavailability and anthelmintic activity of albendazole by preparing albendazolecyclodextrin complexes. Parasite 2001;8:88-90.
25. Gaur RL, Dixit S, Sahoo MK, et al. Anti-filarial activity of novel formulations of albendazole against experimental brugian filariasis. Parasitology 2007;134:537-44.
26. Casulli A, Morales MAG, Gallinella B, et al. 2-Hydroxypropylb- cyclodextrin improves the effectiveness of albendazole against encapsulated larvae of Trichinella spiralis in a murine model. J Antimicrob Chemother 2006;58:886-90 Available from: http://jac.oxfordjournals.org/content/58/4/886. full-aff-2.
27. Bhatt AD, Pethe AM. Nanotechnology: a promising drug delivery for poorly water soluble drugs. J Pharm Res 2010;3:817-48.
28. Liu Y, Xie P, Zhang D, Zhang Q. A mini review of nanosuspensions development. J Drug Target 2012;20:209-23.
29. Gupta AK, Sehrawat SK. Bioavailability enhancement of poorly water soluble drugs: A review. Int J Pharm Life Sci 2011;2:640-50.
30. Rahman MA, Harwansh R, Mirza MA, et al. Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr Drug Deliv 2011;8:330-45.
31. Park YD, Oya A, Otani S. Factors governing the solubility of mesophase into pitch distillate. Fuel 1983;62:1499-502.
32. Bassissi F, Lespine A, Alvinerie M. Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration. Parasitol Res 2006;98:244-9.
33. Wen H, New RR, Muhmut M, et al. Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology 1996;113:111-21.
34. Guerra-caceres JG, Bryceson ADM, Quakyi I, et al. Studies on the mechanisms of adverse reactions produced by diethylcarbamazine in patients with onchocerciasis-Mazzotti reaction. Parasite Immunol 1980;2:121-31.
35. Bindu M Boddupalli, Mohammed ZNK, Ravinder A Nath, et al. Mucoadhesive drug delivery system: an overview. J Adv Pharm Technol Res 2010;1:381-7.
36. Hombach J, Bernkop-Schnürch A. Mucoadhesive drug delivery systems. Exp Pharmacol 2010;197:251-66.
37. Arora S, Ali J, Ahuja A, et al. Floating drug delivery systems: a review. AAPS PharmSciTech 2005;6:372-90.
38. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000;3:235-59.
39. Suresh K Maurya, Pathak K, Vikas Bali. Therapeutic potential of mucoadhesive drug delivery systems-an updated patent review. Recent Pat Drug Deliv Formul 2010;4:256-65.
40. Singla AK, Chawla M, Singh A. Potential applications of carbomer in oral mucoadhesive controlled drug delivery system: a review. Drug Dev Ind Pharm 2000;9:913-24.
41. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 2002;15:355-66.
42. Gadkowski BL, Stout JE. Pharmacokinetics of rifampicin. Clin Infect Dis 2007;44:618-9.
43. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011;153:198-205.
44. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008;77:311-9.
45. Mehra NK, Mishra V, Jain NK. Receptor-based targeting of therapeutics. Ther Deliv 2013;4:369-94.
46. Luo G, Yu X, Jin C, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010;385:150-6.
47. Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci 2001;6:667-80.
48. Hauff P, Reinhardt M, Briel A, et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology 2004;231: 667-73.
49. Cuong NV, Hsieh MF. Molecular targeting of liposomal nanoparticles to lymphatic system. Curr Cancer Drug Targets 2011;11: 147-55.
50. Shivakumar HN, Desai BG, Deshmukh G. Design and optimization of diclofenac sodium controlled release solid dispersions by response surface methodology. Indian J Pharm Sci 2008;70:22-30.
51. Hoffman AS. The origins and evolution of "controlled" drug delivery systems. J Control Release 2008;132:153-63.
52. Gupta RC, Bansal SS, et al. Controlled-release systemic delivery-a new concept in cancer chemoprevention. Carcinogenesis 2012;8: 1608.
53. Shenoy RK. Varghese J, Kuttikkal VV, et al. The efficacy, tolerability and diethylcarbamazine fortified salt in treatment of the microfilaraemias of brugian filariasis: an open, hospital based safety of the study. Ann Trop Med Parasitol 2003;92:285-93.
54. Pani SP, Reddy GS, Das LK, et al. Tolerability and efficacy of single dose of albendazole or diethylcarbamazine (DEC) or co administration of albendazole with DEC in the clearance of Wuchereria bancrofti microfilaria carriers in Pondicherry, south India hospital based study. Filaria J 2002;1:2871-81.
55. Critchley J, Addiss D, Ejere H, et al. Albendazole for the control and elimination of lymphatic filariasis: systematic review. Trop Med Int Health 2005;9:818-25.
56. Sutanto I, Boreham PF, Munawar M, et al. Adverse reaction to a single dose of diethylcarbamazine in patients with Brugia malayi infection in Riau Province, West Indonesia. Southeast Asian J Trop Med Public Health 1985;16:395-400.
57. Haarbrink M, Abadi GK, Buurman WA, et al. Strong association of IL-6 and lipo polysaccharide-binding protein with severity of adverse reactions after DEC treatment of microfilaremic patients. J Infect Dis 2000;182:564-9.
58. Shieh MJ, Hsu CH, Huang LY, et al. Reversal of doxorubicinresistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 2011;152:418-25.
59. Li PY, Lai PS, Hung WC, et al. Poly (L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drugresistant MCF-7 breast cancer cells. Biomacromolecules 2010;11: 2576-82.
60. Wang X, Li J, Wang Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011;23:6184-94.
61. IBM Nanoparticle Breakthrough Destroys Drug-Resistant Bacteria Business 2.0 press. Available from: business2press.com [last accessed 4 April 2011].
62. Slatko BE, Taylor MJ, Foster JM. The Wolbachia endosymbiont as an anti-filarial nematode target. Symbiosis 2010;51:55-65.
63. Taylor MJ. Wolbachia endosymbiotic bacteria of filarial nematodes. A new insight into disease pathogenesis and control. Arch Med Res 2002;33:422-4.
64. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935-40.
65. Oussoren C, Storm G. Subcutaneous administration of liposomes for lymphatic targeting. Adv Drug Deliv Rev 1997;7: 227-40.
66. Kim CK, Han JH. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 1995;12: 437-46.
67. Maincent P. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res 1992;9:1534-9.
68. Reddy ST, Vlies AJ, Simeoni E. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnology 2007;25:1159-64.
69. Ali M, Afzal M, Bhattacharya SM, et al. Nanopharmaceuticals to target antifilarials: a comprehensive review. Expert Opin Drug Deliv 2013;10:665-78.
70. Saraf S, Ghosh A, Kaur CD, et al. Novel modified nanosystems based lymphatic targeting. J Nanosci Nanotechnol 2011;1:60-74.
71. Drobnik J. Hyaluronan in drug delivery. Adv Drug Deliv Rev 1999; 7:295-308.
72. Hauff, P, Reinhard M, Briel A, et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology 2004;231:667-73.
73. Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 2008;16: 798-805.
74. Xie Y, Bagby TR, Cohen MS, et al. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv 2009;6:785-92.
75. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;23:55-64.
76. McElroy M, Hayashi K, Susini BG. Fluorescent LYVE-1 antibody to image dynamically lymphatic trafficking of cancer cells in vivo. J Surg Res 2009;151:68-73.
77. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42:463-78.
78. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 2001;53: 283-318.
79. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315.
80. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006:66.
81. Cardoso MM, Peça IN, Roque AC. Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem 2012;19: 3103-27.
82. Kumar S, Aaron J, Sokolov K. Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties. Nat Protocols 2008;3:314-20. Available from: http://www.nature.com/nprot/journal/v3/n2/full/nprot.2008.1.html
83. Xu H, Aguilar ZP, Yang L. Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials 2011;36
84. Mak JW, Navaratnam V, Ramachandran CP. Experimental chemotherapy of lymphatic filariasis-a review. Ann Trop Med Parasitol 1991;85:131-7.
85. Gupta S, Srivastava AK. Biochemical targets in filarial worms for selective antifilarial drug design. Acta Parasitol 2005;50:1-18.
86. Lazdins J, Kron M. New molecular targets for filariasis drug discovery. Parasitol Today 1999;15:305-6.
87. Townson S, Ramirez B, Fakorede F, et al. Challenges in drug discovery for novel antifilarials. Expert Opin Drug Discov 2007;2: 63-73.
88. Singh SK, Goswami K, Sharma RD, et al. Novel microfilaricidal activity of nanosilver. Int J Nanomedicine 2012;7:1023-30.